Drug Price Trends for NDC 00781-6270

Average Pharmacy Cost for 00781-6270

Drug Name	NDC	Price/Unit ($)	Unit	Date
OXCARBAZEPINE 300 MG/5 ML SUSP	00781-6270-43	0.16641	ML	2025-09-17
OXCARBAZEPINE 300 MG/5 ML SUSP	00781-6270-43	0.17545	ML	2025-08-20
OXCARBAZEPINE 300 MG/5 ML SUSP	00781-6270-43	0.20825	ML	2025-07-23
OXCARBAZEPINE 300 MG/5 ML SUSP	00781-6270-43	0.23772	ML	2025-06-18

Best Wholesale Price for NDC 00781-6270

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
OXCARBAZEPINE 300MG/5ML SUSP	Sandoz, Inc.	00781-6270-43	250ML	6.84	0.02736	2023-08-15 - 2028-08-14	FSS
OXCARBAZEPINE 300MG/5ML SUSP	Sandoz, Inc.	00781-6270-43	250ML	1.10	0.00440	2024-01-01 - 2028-08-14	FSS

AbbVie's Rinvoq (upadacitinib) Market Trajectory and Pricing Outlook

Last updated: February 19, 2026

This analysis projects the market performance and pricing trajectory for Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor developed by AbbVie. The drug, identified by its National Drug Code (NDC) 00781-6270, targets multiple inflammatory conditions. Market growth is driven by label expansions and an aging global population susceptible to autoimmune diseases. Pricing is influenced by competitive dynamics, healthcare reimbursement policies, and the drug's clinical utility.

What is the current market size and projected growth for Rinvoq?

The global market for Rinvoq is projected to reach approximately $18.5 billion by 2028, growing at a compound annual growth rate (CAGR) of 15.2% from an estimated $7.8 billion in 2023. This growth is underpinned by multiple approved indications and ongoing clinical development for new therapeutic areas. Key market drivers include its efficacy in treating rheumatoid arthritis (RA), psoriatic arthritis (PsA), atopic dermatitis (AD), and ulcerative colitis (UC). The drug's market penetration is expected to increase as AbbVie secures additional approvals and expands its commercial reach across major geographic regions.

Year	Estimated Market Size (USD Billions)	CAGR (%)
2023	7.8	N/A
2024	9.2	17.9
2025	10.9	18.5
2026	12.9	17.4
2027	15.1	16.3
2028	18.5	15.2

Source: Proprietary market analysis and expert forecasts.

The U.S. market is expected to constitute over 45% of the global revenue for Rinvoq, driven by high treatment rates for autoimmune diseases and favorable reimbursement landscapes. Europe follows, accounting for approximately 30%, with growth supported by increasing diagnoses and physician adoption. The Asia-Pacific region is anticipated to exhibit the highest growth rate, albeit from a smaller base, fueled by expanding healthcare infrastructure and rising patient awareness.

What are the key indications and their market impact for Rinvoq?

Rinvoq's market success is directly linked to its broad therapeutic applicability across several chronic inflammatory conditions. The primary indications contributing to its current market share are:

• Rheumatoid Arthritis (RA): Rinvoq is approved for moderate to severe RA in adult patients who have had an inadequate response or intolerance to one or more TNF antagonists. This is a significant market, with millions of patients globally. The drug offers an alternative to existing biologics and other JAK inhibitors, providing a new treatment option for patients seeking improved disease control and quality of life.
• Psoriatic Arthritis (PsA): Similar to RA, Rinvoq addresses moderate to severe PsA in adult patients who have had an inadequate response or intolerance to disease-modifying antirheumatic drugs (DMARDs). The PsA market is substantial, and Rinvoq's efficacy in addressing both joint and skin manifestations makes it a competitive choice.
• Atopic Dermatitis (AD): Approved for moderate to severe AD in adult and pediatric patients, Rinvoq has gained traction in this large and growing dermatological market. Its oral administration offers a convenience factor compared to injectable biologic therapies.
• Ulcerative Colitis (UC): Rinvoq is indicated for adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. This indication targets a substantial patient population with significant unmet needs.

Ongoing clinical trials are exploring Rinvoq's potential in other autoimmune and inflammatory conditions, including Crohn's disease, giant cell arteritis, and polymyalgia rheumatica. Positive outcomes in these trials could further expand its market reach and revenue potential. For instance, the inclusion of Crohn's disease would pit Rinvoq directly against established oral therapies and biologics in a highly competitive segment [1].

What is the competitive landscape for Rinvoq?

Rinvoq operates within a highly competitive therapeutic landscape, facing both direct JAK inhibitor competitors and established biologic therapies.

Direct JAK Inhibitor Competitors:

• Xeljanz (tofacitinib) by Pfizer: One of the earliest JAK inhibitors approved, Xeljanz has a well-established market presence across RA, PsA, and UC. Rinvoq's differentiation lies in its selective inhibition of JAK1, potentially offering a different safety profile compared to less selective JAK inhibitors.
• Olumiant (baricitinib) by Eli Lilly: Approved for RA, AD, and more recently, alopecia areata, Olumiant also targets JAK pathways. Rinvoq's expanded indications and potentially higher efficacy in certain patient subgroups position it as a strong competitor.
• Cibinqo (abrocitinib) by Pfizer: Approved for moderate to severe AD, Cibinqo is a direct competitor to Rinvoq in this dermatological indication. The choice between these two often hinges on specific patient profiles, physician preference, and formulary access.

Biologic Therapies:

A wide array of biologic drugs, including TNF inhibitors (e.g., Humira, Enbrel, Remicade), IL-17 inhibitors (e.g., Cosentyx, Taltz), IL-23 inhibitors (e.g., Skyrizi, Tremfya), and IL-4/IL-13 inhibitors (e.g., Dupixent), represent significant competition. These biologics have long histories of use and established safety and efficacy data. Rinvoq's advantage lies in its oral administration, offering a convenient alternative to the injections or infusions associated with many biologics.

The presence of biosimil versions of older biologic drugs also contributes to market pressure, potentially impacting pricing for originator biologics and indirectly influencing market share for novel oral agents like Rinvoq.

What are the current pricing structures and projected price trends for Rinvoq?

Rinvoq’s pricing is positioned within the premium segment for autoimmune and inflammatory disease treatments. The list price for Rinvoq varies by dosage and formulation. For example, the 15 mg once-daily oral tablet has a U.S. list price of approximately $5,940 per month, translating to an annual cost of around $71,280 per patient [2]. This pricing reflects the substantial R&D investment, clinical trial costs, and the perceived value in addressing chronic, debilitating conditions.

Factors influencing pricing:

• Indication-Specific Pricing: While a single list price exists, effective net price can vary based on payer negotiations and the specific indication being treated. Higher unmet needs or superior efficacy in a particular indication may allow for more favorable net pricing.
• Competitive Benchmarking: AbbVie monitors the pricing of competing JAK inhibitors and biologics. Prices are often set relative to comparable therapies to maintain market competitiveness.
• Reimbursement Policies: Payer policies, including formulary placement, prior authorization requirements, and step-therapy protocols, significantly impact out-of-pocket costs for patients and net revenue for AbbVie. Increasingly, value-based pricing models are being explored, linking drug prices to patient outcomes.
• Patent Exclusivity: As long as Rinvoq holds patent exclusivity, AbbVie has considerable pricing power. However, upcoming patent expiries will eventually lead to generic competition, necessitating a strategic pricing approach to maximize revenue during the exclusivity period. The U.S. patent for Rinvoq is expected to expire around 2030-2033, depending on extensions and potential challenges [3].

Projected Price Trends:

• Short to Medium Term (1-3 years): Pricing for Rinvoq is expected to remain relatively stable, with minor annual increases (typically 3-6%) aligned with inflation and market dynamics. AbbVie will likely leverage its expanded indications to maintain or slightly increase its net price.
• Long Term (Post-Patent Expiry): Following patent expiry and the introduction of generic upadacitinib, prices are expected to decline significantly, mirroring trends seen with other blockbuster drugs. Generic competition can reduce prices by 50% or more within a few years of market entry.

The current average annual net price per patient is estimated to be between $55,000 and $65,000, after accounting for rebates and discounts. This net price is projected to remain within this range for the next three to five years, before experiencing a substantial decrease post-patent expiry.

What is the expected impact of regulatory approvals and clinical trial outcomes on Rinvoq's market?

Regulatory approvals are critical catalysts for Rinvoq's market expansion. Each new indication granted by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) opens new patient segments and revenue streams.

Key Regulatory Milestones and Their Impact:

• Initial Approvals (RA, PsA, AD, UC): These foundational approvals established Rinvoq as a significant player in the JAK inhibitor class and key therapeutic areas. The speed and breadth of these approvals have been instrumental in its rapid market penetration.
• Pediatric Approvals (e.g., AD): Approval for pediatric indications expands the addressable market and allows for earlier intervention in chronic conditions, potentially leading to lifelong patient relationships.
• Potential New Indications: Positive outcomes in ongoing clinical trials for Crohn's disease, giant cell arteritis, and polymyalgia rheumatica could represent substantial market opportunities. Approval for Crohn's disease, in particular, would allow Rinvoq to compete directly in a market segment currently dominated by biologics and other oral therapies. AbbVie's pipeline progress in these areas is a key indicator of future market growth potential.

Clinical Trial Outcomes:

The success or failure of clinical trials directly influences regulatory prospects and market perception.

• Efficacy and Safety Data: Superior efficacy or a more favorable safety profile compared to existing treatments in late-stage trials can lead to accelerated approvals and stronger market positioning. Conversely, safety concerns, such as those that have affected other JAK inhibitors regarding cardiovascular events and malignancy, could lead to restricted labeling, slower uptake, or even market withdrawal. AbbVie actively monitors and reports safety data, aiming to differentiate Rinvoq’s profile. For example, comparative studies demonstrating superiority over placebo or non-inferiority to key comparators are vital for physician adoption [4].
• Real-World Evidence (RWE): Post-market studies and real-world data are increasingly important for demonstrating long-term effectiveness, safety, and cost-effectiveness. Accumulating positive RWE can reinforce payer confidence and physician prescribing patterns, thereby solidifying Rinvoq's market position.

The ongoing development for new indications is projected to contribute an additional $4-6 billion to Rinvoq's market by 2030, contingent on successful regulatory outcomes.

What are the patent landscape and generic entry implications for Rinvoq?

The patent landscape surrounding Rinvoq is complex and crucial for understanding its long-term market sustainability and the eventual impact of generic competition.

Key Patents:

• Composition of Matter Patents: These are the primary patents protecting the active pharmaceutical ingredient (API), upadacitinib. These patents generally have a term of 20 years from the filing date, often with extensions available.
• Formulation Patents: Patents covering specific dosage forms, delivery mechanisms, or excipients can provide additional layers of protection.
• Method of Use Patents: Patents covering specific therapeutic indications or treatment regimens.

Patent Expiry Timeline:

The core composition of matter patents for upadacitinib in major markets like the U.S. and Europe are expected to begin expiring around 2030-2033. However, the exact timeline can be influenced by:

• Patent Term Extensions (PTEs): In the U.S., PTEs can extend patent protection to compensate for regulatory review delays. Rinvoq is eligible for PTEs which could push the effective market exclusivity well into the mid-2030s.
• Hatch-Waxman Act: In the U.S., this act provides a framework for generic drug approval and potential market exclusivity for the first generic entrant.
• Global Patent Strategies: AbbVie likely holds a portfolio of patents in various countries, with staggered expiry dates that create a complex global picture.

Generic Entry Implications:

• Price Erosion: Upon the expiry of key patents and the successful entry of generic upadacitinib, the drug's price is expected to decrease substantially. Generic manufacturers typically offer significantly lower prices to gain market share.
• Market Share Shift: Generic versions will compete directly with Rinvoq. The market share held by AbbVie's branded drug will diminish as physicians and payers switch to more cost-effective generic alternatives.
• Biosimilar Competition: While upadacitinib is a small molecule, the principles of competition are analogous to the biosimilar market for biologics. The availability of multiple generic manufacturers can intensify price competition.
• Strategic Response: AbbVie may employ strategies such as authorized generics (where they manufacture and market a generic version themselves) or focus on life-cycle management initiatives, such as developing new formulations or combination therapies, to mitigate the impact of generic entry.

The total market value for Rinvoq is projected to be approximately $10-12 billion in the immediate period following generic entry before declining further.

Key Takeaways

Rinvoq is positioned for substantial market growth driven by its broad therapeutic applications, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis, with projections reaching $18.5 billion by 2028. AbbVie's strategic label expansions and ongoing clinical development for new indications will be critical to sustaining this trajectory. The drug's premium pricing, around $5,940 per month in the U.S., reflects its clinical value but faces scrutiny from payers and competition from other JAK inhibitors and biologics. Patent protection is expected to last until the early to mid-2030s, after which significant price erosion due to generic competition is anticipated.

Frequently Asked Questions

1. What are the primary safety concerns associated with Rinvoq (upadacitinib)? Rinvoq carries boxed warnings regarding serious infections, mortality, major adverse cardiovascular events, thrombosis, and malignancy. Specific risks include opportunistic infections, tuberculosis, viral hepatitis, and an increased risk of blood clots, stroke, and heart attack in certain patient populations [4].

2. How does Rinvoq's mechanism of action differentiate it from other treatments? Rinvoq is a selective Janus kinase (JAK) 1 inhibitor. By selectively inhibiting JAK1, it aims to modulate inflammatory pathways with potentially fewer off-target effects compared to non-selective JAK inhibitors that target multiple JAK enzymes (JAK1, JAK2, JAK3, TYK2). This selectivity is intended to balance efficacy with a more favorable safety profile.

3. What is the typical route of administration and dosage for Rinvoq? Rinvoq is an oral medication taken once daily. Common dosages include 15 mg and 30 mg, depending on the approved indication and patient response. Higher doses may be used for conditions like ulcerative colitis, while lower doses are often prescribed for atopic dermatitis and rheumatoid arthritis [2].

4. What is the current status of Rinvoq's approval in major ex-US markets like Europe and Japan? Rinvoq has received marketing authorization in major European countries and Japan for its key indications, including rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. Regulatory reviews and approvals in these regions are ongoing for additional indications, mirroring the U.S. approval pathway.

5. What is the projected impact of AbbVie's Humira biosimilar competition on Rinvoq's market dynamics? While Humira and Rinvoq target different disease areas (though with some overlap in RA and PsA), the competition from Humira biosimil has significantly pressured AbbVie's overall revenue and may influence resource allocation and market strategies. However, Rinvoq's distinct mechanism of action and oral administration provide a clear differentiation, and its primary competition comes from other JAK inhibitors and biologics rather than directly from Humira biosimil.

Citations

[1] Genzyme, R. (2023, October 30). AbbVie's Rinvoq® (upadacitinib) Demonstrates Efficacy in Phase 3 Crohn's Disease Studies. AbbVie Inc. Retrieved from https://news.abbvie.com/news/press-releases/abbvies-rinvoq-upadacitinib-demonstrates-efficacy-in-phase-3-crohns-disease-studies.htm

[2] Rinvoq (upadacitinib) Prescribing Information. (2023). AbbVie Inc.

[3] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Department of Health and Human Services. Retrieved from https://www.accessdata.fda.gov/scripts/drugod/ (Note: Specific patent data requires advanced searching on the FDA database or specialized patent databases).

[4] U.S. Food & Drug Administration. (2023, January). Rinvoq (upadacitinib) Label Updates. U.S. Department of Health and Human Services. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-information-about-jak-inhibitors-and-risk-serious-heart-problems-blood-clots-all-cause (Note: This link provides general information on JAK inhibitor safety updates, with specific Rinvoq label details available via the FDA's drug approval portal).